NOVO-NORDISK AS BDK 0.1 news, videos and press releases
For more news please use our advanced search feature.
NOVO-NORDISK AS BDK 0.1 - More news...
NOVO-NORDISK AS BDK 0.1 - More news...
- Novo Nordisk A/S: CagriSema demonstrates superior weight loss in adults with obesity or overweight and type 2 diabetes in the REDEFINE 2 trial
- Novo Nordisk A/S: Notice for the Annual General Meeting of Novo Nordisk A/S
- Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons
- Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons
- Novo Nordisk's sales increased by 25% in Danish kroner and by 26% at constant exchange rates to DKK 290.4 billion in 2024
- Novo Nordisk A/S - share repurchase programme
- Novo Nordisk A/S - share repurchase programme
- Novo Nordisk successfully completes phase 1b/2a trial with subcutaneous amycretin in people with overweight or obesity
- Novo Nordisk A/S - share repurchase programme
- Novo Nordisk A/S: Semaglutide 7.2 mg s.c. achieved 20.7% weight loss in the STEP UP obesity trial, and 18.7% regardless of treatment adherence
- Novo Nordisk A/S - share repurchase programme
- Valo Health and Novo Nordisk expand collaboration to discover and develop novel treatments for cardiometabolic diseases
- Novo Nordisk A/S - share repurchase programme
- Novo Nordisk A/S: CagriSema demonstrates superior weight loss in adults with obesity or overweight in the REDEFINE 1 trial
- The acquisition of Catalent by Novo Holdings, and the related acquisition by Novo Nordisk of three manufacturing sites from Novo Holdings, is completed
- Novo Nordisk A/S - share repurchase programme
- Novo Nordisk A/S: The acquisition of Catalent by Novo Holdings, and the related acquisition by Novo Nordisk of three manufacturing sites from Novo Holdings, is cleared to close
- Novo Nordisk A/S: European regulatory authority adopts positive opinion for an update of the Ozempic® label to reflect risk reduction of kidney disease-related events
- Novo Nordisk A/S - share repurchase programme
- The European Commission approves the acquisition of Catalent by Novo Holdings and the related acquisition by Novo Nordisk of three manufacturing sites from Novo Holdings
- Novo Nordisk A/S - share repurchase programme
- Novo Nordisk A/S - share repurchase programme
- Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons
- Novo Nordisk A/S - share repurchase programme
- Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons
- Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons
- Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons
- Novo Nordisk A/S - share repurchase programme
- Novo Nordisk A/S purchases B shares worth DKK 4,736 million from Novo Holdings A/S under the 2024 share repurchase programme
- Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons
